Equities

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)350.70
  • Today's Change-4.15 / -1.17%
  • Shares traded454.43k
  • 1 Year change+144.61%
  • Beta-0.4146
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform8
Hold3
Sell1
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Madrigal Pharmaceuticals Inc have a median target of 390.00, with a high estimate of 530.00 and a low estimate of 155.00. The median estimate represents a 11.21% increase from the last price of 350.70.
High51.1%530.00
Med11.2%390.00
Low-55.8%155.00

Earnings history & estimates in USD

On Oct 31, 2024, Madrigal Pharmaceuticals Inc reported 3rd quarter 2024 losses of -4.92 per share. This result exceeded the -6.91 consensus loss of the 15 analysts covering the company and exceeded last year's 3rd quarter results by 7.87%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-0.45%
Madrigal Pharmaceuticals Inc reported annual 2023 losses of -19.99 per share on Feb 28, 2024.
Average growth rate-46.43%
More ▼

Revenue history & estimates in USD

Madrigal Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 62.18m. This bettered the 34.19m consensus of the 15 analysts covering the company.
Average growth rate+108.25%
Madrigal Pharmaceuticals, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.